Daily Stock Analysis, CTLT, Catalent Inc, priceseries

Catalent, Inc. is a holding company, which engages in the research, development and marketing of pharmaceutical products. It operates through the following segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment engages in formulation, development and manufacturing of prescription and consumer health soft capsules, or softgels including traditional softgel capsules; and vegicaps and optishell capsules. The Drug Delivery Solutions segment includes formulation, development and manufacturing of prescription and consumer and animal health products using its proprietary optimelt, optipact, optiform and zydis technologies, other proprietary and conventional drug delivery technologies such as prefilled syringes; blow-fill seal unit dose manufacturing including its ADVASEPT technology; biologic cell line development including its GPEx and SMARTag technologies; and analytical and bioanalytical development; and testing services. The Clinical Supply Services segment includes in manufacturing, packaging, labeling, storage, distribution and inventory management for global clinical trials of drugs and biologics for customer required patient kits; fastChain demand-led clinical supply service; clinical e-solutions and informatics; and global comparator sourcing services. The company was founded in April 2007 and is headquartered in Somerset, NJ.

Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for softgels, which are used in a range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, and Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using proprietary technologies, including OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose, including ADVASEPT technology; develops biologic cell line, including GPEx and SMARTag technologies; and provides analytical and bioanalytical development, and testing services, as well as offers respiratory products formulation and manufacturing, micronization and particle engineering, and regulatory consulting services. The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials for customer required patient kits. This segment also offers FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical and biotechnology companies; and consumer health companies, as well as companies in other healthcare market segments, such as animal health and medical devices, and companies in industries, including cosmetics. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.